Skip to main content

Equibles does not estimate personal net worth.

About Keith Goldan

Keith Goldan is recorded as CFO at Option Therapeutics Inc. (OPTN) and CFO at Syndax Pharmaceuticals Inc (SNDX). The proxy statement of Syndax Pharmaceuticals Inc reports total compensation of $2,470,802 for Keith Goldan in fiscal 2025, including a base salary of $516,900. Disclosed compensation is on record for 4 fiscal years. Keith Goldan has spoken on 20 earnings calls across 2 companies, most recently for Syndax Pharmaceuticals Inc on August 4, 2026. Those appearances were for Syndax Pharmaceuticals Inc (SNDX) and Option Therapeutics Inc. (OPTN). Syndax Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Syndax Pharmaceuticals Inc includes Michael A. Metzger (CEO and Board Member), Michael Metzger (CEO), Aaron A. Ondrey (CFO and Chief Accounting Officer) and 6 others.

Keith Goldan on recent calls

“Earlier this afternoon, we reported detailed second quarter 2026 financial results, and I'll highlight a few key points on slide 12. Total revenue for the second quarter of 2026 was $72.8 million, up 92% over the same period last year.”
CFO, Syndax Pharmaceuticals Inc Q2 FY2026 Earnings Call ·
“Earlier this afternoon, we reported detailed fourth quarter and full year 2025 financial results. I'll highlight just a few key points on slide 14.”
CFO, Syndax Pharmaceuticals Inc Q4 FY2025 Earnings Call ·
“Earlier this afternoon, we reported detailed third quarter 2025 financial results. I will touch on a few key points on Slide 14. For the third quarter of 2025, we reported Revuforj net revenue of $32 million.”
CFO, Syndax Pharmaceuticals Inc Q3 FY2025 Earnings Call ·
“Earlier this afternoon, we reported detailed second quarter 2025 financial results, and I'll touch on a few of these key points on Slide 12. For the second quarter of 2025, we reported Revuforj net revenue of $28.6 million.”
CFO, Syndax Pharmaceuticals Inc Q2 FY2025 Earnings Call ·
“Earlier this afternoon, we reported detailed first quarter 2025 financial results in our press release and Form 10-Q. For today's call, I'll touch upon a few key points on slide 12.”
CFO, Syndax Pharmaceuticals Inc Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Syndax Pharmaceuticals Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Syndax Pharmaceuticals Inc (SNDX) $516,900 $2,470,802
2024 Syndax Pharmaceuticals Inc (SNDX) $497,000 $2,824,133
2023 Syndax Pharmaceuticals Inc (SNDX) $470,300 $2,826,034
2022 Syndax Pharmaceuticals Inc (SNDX) $249,900 $2,992,538

Recent activity

Show 8 earlier activities